@avirupguha @BloodJournal @datsunian @onco_cardiology @TomasNeilan @Dr_Mike_Fradley @ICOSociety @Cardioonc_bot @NCICancerCtrl @OSUCCC_James More (cv) focused monitoring needed as events can be missed: https://t.co/gP0NUvz55W https://t.co/HYd9tURHk1
RT @ACCinTouch: Access this Central Illustration⬇️along with the full study from @JACCJournals here: https://t.co/K3gkPzXFNY #CardioOnc #…
RT @ACCinTouch: Access this Central Illustration⬇️along with the full study from @JACCJournals here: https://t.co/K3gkPzXFNY #CardioOnc #…
RT @ACCinTouch: Access this Central Illustration⬇️along with the full study from @JACCJournals here: https://t.co/K3gkPzXFNY #CardioOnc #…
RT @ACCinTouch: Access this Central Illustration⬇️along with the full study from @JACCJournals here: https://t.co/K3gkPzXFNY #CardioOnc #…
RT @ACCinTouch: Access this Central Illustration⬇️along with the full study from @JACCJournals here: https://t.co/K3gkPzXFNY #CardioOnc #…
RT @ACCinTouch: Access this Central Illustration⬇️along with the full study from @JACCJournals here: https://t.co/K3gkPzXFNY #CardioOnc #…
RT @ACCinTouch: Access this Central Illustration⬇️along with the full study from @JACCJournals here: https://t.co/K3gkPzXFNY #CardioOnc #…
Access this Central Illustration⬇️along with the full study from @JACCJournals here: https://t.co/K3gkPzXFNY #CardioOnc #ACCEd #CardioTwitter #Cancer
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
RT @md_addison: @ElisaAgostinett @eiger_daniel @noam_ponde @matteolambe @E_de_Azambuja @JulesBordet @OncoAlert Outstanding effort by a grea…
RT @md_addison: @ElisaAgostinett @eiger_daniel @noam_ponde @matteolambe @E_de_Azambuja @JulesBordet @OncoAlert Outstanding effort by a grea…
@ElisaAgostinett @eiger_daniel @noam_ponde @matteolambe @E_de_Azambuja @JulesBordet @OncoAlert Outstanding effort by a great team. A little worried on the reliability of these findings based on trials though (https://t.co/s7I0lbsJGQ). #cardioonc @avirupgu
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
Please read the data!
RT @md_addison: Hopeful that this 2020 study will propel closer cardiac consideration in future cancer trials. https://t.co/E7TLZMgUqn. @AB…
RT @md_addison: Hopeful that this 2020 study will propel closer cardiac consideration in future cancer trials. https://t.co/E7TLZMgUqn. @AB…
Hopeful that this 2020 study will propel closer cardiac consideration in future cancer trials. https://t.co/E7TLZMgUqn. @ABCardio1 @janicebonsu thank you to my co-authors in aiding in this effort.
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
RT @JIM_AFMR: Excellent reporting and an important article: Among pivotal clinical trials linked to contemporary FDA-approved cancer drugs,…
Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co/SmK4WDvqhe
RT @JIM_AFMR: Excellent reporting and an important article: Among pivotal clinical trials linked to contemporary FDA-approved cancer drugs,…
RT @JIM_AFMR: Excellent reporting and an important article: Among pivotal clinical trials linked to contemporary FDA-approved cancer drugs,…
Excellent reporting and an important article: Among pivotal clinical trials linked to contemporary FDA-approved cancer drugs, reported CVD event rates trail expected population rates https://t.co/q1r9pl8UIH #cardioonc #meded #medtwiiter @avirupguha @janice
RT @JACCJournals: #CVD has become a common limitation to anticancer-therapy, yet it is unknown whether CV events are consistently reported…
Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies. J Am Coll Cardiol #cancer #epidemiology https://t.co/IZ8fBGiYIW
RT @JACCJournals: Among pivotal clinical trials linked to @FDA approved #cancer drugs, reported #CVD event rates trail expected population…
RT @JACCJournals: Among pivotal clinical trials linked to @FDA approved #cancer drugs, reported #CVD event rates trail expected population…
RT @JACCJournals: Among pivotal clinical trials linked to @FDA approved #cancer drugs, reported #CVD event rates trail expected population…
RT @JACCJournals: Among pivotal clinical trials linked to @FDA approved #cancer drugs, reported #CVD event rates trail expected population…
RT @JACCJournals: Among pivotal clinical trials linked to @FDA approved #cancer drugs, reported #CVD event rates trail expected population…
Among pivotal clinical trials linked to @FDA approved #cancer drugs, reported #CVD event rates trail expected population rates. Enhanced focus on the nature of cardiotoxicity-risk from published clinical trials is needed. #JACC https://t.co/TsbBXMEj2Y @OSU
RT @rhythmkris: thought provoking analysis of 123 pivotal approval trials for #oncology drugs- 40% did not report ANY CVD events in follow…
RT @md_addison: Thank you to the editorial team at JACC for allowing us to bring forth this timely work. I am honored and excited to hel…
RT @JACCJournals: #CVD has become a common limitation to anticancer-therapy, yet it is unknown whether CV events are consistently reported…
RT @rhythmkris: thought provoking analysis of 123 pivotal approval trials for #oncology drugs- 40% did not report ANY CVD events in follow…
thought provoking analysis of 123 pivotal approval trials for #oncology drugs- 40% did not report ANY CVD events in follow up. In trials that did report, the rate was markedly lower than in #MESA data (RR 0.38(!)). Correct comparator? #CardioOnc https://t.
Thank you to the editorial team at JACC for allowing us to bring forth this timely work. I am honored and excited to help lead the effort in addressing this issue.
RT @JACCJournals: #CVD has become a common limitation to anticancer-therapy, yet it is unknown whether CV events are consistently reported…
RT @JACCJournals: #CVD has become a common limitation to anticancer-therapy, yet it is unknown whether CV events are consistently reported…
RT @JACCJournals: #CVD has become a common limitation to anticancer-therapy, yet it is unknown whether CV events are consistently reported…
#CVD in #anticancer-therapy is underestimated. Every #cancer patient is a CVD patient.
RT @JACCJournals: #CVD has become a common limitation to anticancer-therapy, yet it is unknown whether CV events are consistently reported…
RT @JACCJournals: #CVD has become a common limitation to anticancer-therapy, yet it is unknown whether CV events are consistently reported…
RT @JACCJournals: #CVD has become a common limitation to anticancer-therapy, yet it is unknown whether CV events are consistently reported…
RT @JACCJournals: #CVD has become a common limitation to anticancer-therapy, yet it is unknown whether CV events are consistently reported…
RT @JACCJournals: #CVD has become a common limitation to anticancer-therapy, yet it is unknown whether CV events are consistently reported…
RT @JACCJournals: #CVD has become a common limitation to anticancer-therapy, yet it is unknown whether CV events are consistently reported…
RT @JACCJournals: #CVD has become a common limitation to anticancer-therapy, yet it is unknown whether CV events are consistently reported…
#CVD has become a common limitation to anticancer-therapy, yet it is unknown whether CV events are consistently reported in pivotal #cancer trials. Using data from the Drugs @US_FDA database, Dr. @md_addison and colleagues reveal reporting trends. https://
RT @dr_manisty: Such important data highlighting the gap between oncology clinical trials and real- world experiences. Time to ensure patie…
RT @husam247: This is why observational studies have a strong role to play in #cardiooncology. While studies can be designed better, there…
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
RT @dr_manisty: Such important data highlighting the gap between oncology clinical trials and real- world experiences. Time to ensure patie…
RT @dr_manisty: Such important data highlighting the gap between oncology clinical trials and real- world experiences. Time to ensure patie…
RT @dr_manisty: Such important data highlighting the gap between oncology clinical trials and real- world experiences. Time to ensure patie…
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
RT @dr_manisty: Such important data highlighting the gap between oncology clinical trials and real- world experiences. Time to ensure patie…
RT @dr_manisty: Such important data highlighting the gap between oncology clinical trials and real- world experiences. Time to ensure patie…
Such important data highlighting the gap between oncology clinical trials and real- world experiences. Time to ensure patients with CV disease are recruited into trials and definitions of CV events are unified. #cardioonc @arjunkg @onco_cardiology
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
RT @husam247: This is why observational studies have a strong role to play in #cardiooncology. While studies can be designed better, there…
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
Great work!!! @avirupguha !
Excellent work @avirupguha @janicebonsu and team..
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
RT @husam247: This is why observational studies have a strong role to play in #cardiooncology. While studies can be designed better, there…
This is why observational studies have a strong role to play in #cardiooncology. While studies can be designed better, there will always be a pressure to select patients with less non-cancer comorbidity for recruitment in RCTs
Truly honored to see this come forward. Foundational relevancy to the field of cardio-oncology. https://t.co/kFv7XYfh25 thank you to my team and collaborators, as well as the editors at JACC.
【抗がん剤承認時、心毒性は正しく評価されている?/ JACC】 FDAへの抗がん剤承認申請試験189報 [97365例] 解析:CVイベントが報告されていたのは62.4%。介入群における加重平均発生率 [?] は716/10万例・年。同年代のがん以外を対象とした試験に比べ、RRは0.38 [p<0.01]。 https://t.co/RJnsJbWvXZ https://t.co/MWRmSPNdRX
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
RT @avirupguha: Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co…
Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies https://t.co/yCYQXvtejK